Clearmind Medicine Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Adi Zuloff-Shani

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	2.8yrs
Participación del CEO	n/a
Permanencia media de la dirección	2.6yrs
Promedio de permanencia en la Junta Directiva	2.6yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Adi Zuloff-Shani en comparación con los beneficios de Clearmind Medicine?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jan 31 2024	n/a	n/a	-US$8m
Oct 31 2023	n/a	n/a	-US$9m
Jul 31 2023	n/a	n/a	-US$6m
Apr 30 2023	n/a	n/a	-US$7m
Jan 31 2023	n/a	n/a	-US$7m
Oct 31 2022	n/a	n/a	-US$7m
Jul 31 2022	n/a	n/a	-US$7m
Apr 30 2022	n/a	n/a	-US$7m
Jan 31 2022	n/a	n/a	-US$4m
Oct 31 2021	US$145k	US$113k	-US$3m

Compensación vs. Mercado: Datos insuficientes para determinar si la compensación total de Adi es razonable en comparación con empresas de tamaño similar en el mercado US.

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Adi con los resultados de la empresa.

CEO

Adi Zuloff-Shani (54 yo)

2.8yrs

Permanencia

Dr. Adi Zuloff-Shani, Ph D., serves as Member of Scientific Advisory Board at N2OFF, Inc. (formerly known as Save Foods, Inc.) since October 2021. She serves as Chief Executive Officer of Clearmind Medicin...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Adi Zuloff-Shani	Chief Executive Officer	2.8yrs	sin datos	sin datos
Alan Rootenberg	Chief Financial Officer	1.9yrs	sin datos	0% $ 0
Mark Haden	Vice President of Business Development	2.8yrs	sin datos	0% $ 0
Gilad Babchuk	Head of Strategy & Communication	2.3yrs	sin datos	sin datos

2.6yrs

Permanencia media

68yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de CMND se considera experimentado (2.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Mark Haden	Vice President of Business Development	2.8yrs	sin datos	0% $ 0
John Krystal	Member of Scientific Advisory Board	1.9yrs	sin datos	sin datos
Michael Davidson	Member of Scientific Advisory Board	no data	sin datos	sin datos
Alon Friedman	Member of Scientific Advisory Board	no data	sin datos	sin datos
Wim van den Brink	Member of Scientific Advisory Board	2.6yrs	sin datos	sin datos
Oz Adler	Independent Director	2.4yrs	sin datos	0.0035% $ 138.2
Amitai Weiss	Independent Chairman	4.8yrs	sin datos	0% $ 0
Yehonatan Shachar	Independent Director	4.1yrs	sin datos	0% $ 0
Gabriele Fischer	Member of Scientific Advisory Board	2.6yrs	sin datos	sin datos
Gal Yadid	Member of Scientific Advisory Board	no data	sin datos	sin datos
Christian Schutz	Member of Scientific Advisory Board	2yrs	sin datos	sin datos
Asaf Itzhaik	Director	1.4yrs	sin datos	sin datos

2.6yrs

Permanencia media

55.5yo

Promedio de edad

Junta con experiencia: La junta directiva de CMND no se considera experimentada (2.5 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Clearmind Medicine Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Clearmind Medicine Inc., Annual General Meeting, Oct 19, 2023

Clearmind Medicine Inc. Appoints Dr. Fatima Cody Stanford, Associate Professor of Medicine At Massachusetts General Hospital and Harvard Medical School, to Its Scientific Advisory Board

Clearmind Medicine Inc. Announces Board Appointments

Clearmind Medicine Inc., Annual General Meeting, Dec 28, 2022

Clearmind Medicine Inc. Appoints John Krystal to its Scientific Advisory Board

Clearmind Medicine Inc. Announces the Resignation of Oded Gilboa as Director

Recent updates

Clearmind Medicine Inc. Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product

Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders

Clearmind Medicine Inc. Announces International Patent Application for Preventing and Treating Depression

Clearmind Medicine Receives Approval for Voluntary Delisting of its Common Shares from the Canadian Securities Exchange

Clearmind Medicine Obtains Clearance for Its Psychedelic- Based Alcoholism Clinical Trial

Clearmind Medicine Inc. Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Clearmind Medicine Inc. Receives Divisional Patent Approval by the China National Intellectual Property Administration

Clearmind Medicine Inc. has completed a Follow-on Equity Offering in the amount of CAD 2.4 million.

Clearmind Medicine Inc. has completed a Follow-on Equity Offering.

Clearmind Medicine Inc. has filed a Follow-on Equity Offering.

Clearmind Medicine Announces Compliance with All Applicable Nasdaq Listing Standards

Scisparc Ltd. and Clearmind Medicine Inc. Announces Obesity Drug Showed Positive Results in A Pre-Clinical Trial

Scisparc Ltd. Obesity Drug Showed Positive Results in A Pre-Clinical Trial

Clearmind Medicine Announces Positive Results from Its Weight Loss and Metabolic Disorder Program with Its Proprietary Psychedelic- Based Treatment

Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice

Clearmind Medicine Inc. to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities

Clearmind Medicine Inc. announced that it expects to receive $2.25 million in funding

Clearmind Medicine Inc., Annual General Meeting, Oct 19, 2023

SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Continues to Increase Its Patent Portfolio in the Field of Movement Abnormalities in the U.S

Clearmind Medicine Inc. Appoints Dr. Fatima Cody Stanford, Associate Professor of Medicine At Massachusetts General Hospital and Harvard Medical School, to Its Scientific Advisory Board

Clearmind Medicine Announces First US Site for Its Phase I/IIa Clinical Trial Evaluating Cmnd-100 in Patients with Alcohol Use Disorder

Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification

Clearmind Medicine Announces Irb Approval to Conduct Clinical Trial on Alcohol Use Disorder

Clearmind Medicine Inc. Announces Board Appointments

Clearmind Medicine Inc. Files Three Provisional Patent Applications with the United States Patent and Trademark Office

Clearmind Medicine Inc. Announces Positive Pre-Clinical Results Treating Major Depression with A Novel Ketamine-Based Compound

SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment

Clearmind Medicine Inc. Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial

Clearmind Medicine Inc. Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Inc. Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial

Clearmind Medicine Inc. Completes IND-Enabling Studies for CMND-100

Clearmind Medicine Inc. Announces Initiation of CMND-100 Manufacturing Program to Address Its Upcoming Clinical Trial

Clearmind Medicine Inc. Common Shares Deleted from OTC Equity

Clearmind Applies for Patent to Treat Obesity and Metabolic Syndrome

Clearmind Medicine Inc., Annual General Meeting, Dec 28, 2022

Clearmind Medicine Announces Additional Positive Pre-Clinical Results for Its Cocaine Addiction Treatment

Clearmind Medicine Inc. Appoints John Krystal to its Scientific Advisory Board

Clearmind Medicine Inc. Announces the Resignation of Oded Gilboa as Director

Clearmind Medicine Inc. Announces CFO Changes

Clearmind Medicine Inc. and SciSparc Ltd Collaboration Yields New Provisional Patent Application for Psychedelic Combination Treatment for Binge Behaviors

Clearmind Medicine Announces Positive Pre-Clinical Results for Cocaine Addiction Treatment

Clearmind Medicine Inc. and Scisparc Collaboration Yields Another Patent Application for Cocaine Addiction Treatment

Clearmind Medicine and SciSparc Collaboration Yields Positive Results for its Psychedelic Combination Treatment

Clearmind Medicine and SciSparc Collaboration Yields Positive Results for its Psychedelic Combination Treatment

Clearmind Medicine Inc. Announces Successful Pre-Clinical Results in MEAI Treatment for Alcohol Consumption

SciSparc Ltd. and Clearmind Medicine Inc. Collaborations Yields New Patent Application for Psychedelic Combination Treatment for Binge Behaviors

Clearmind Medicine Inc. Announces the Appointment of Two New Members to Its Scientific Advisory Board

Clearmind Medicine Inc. announced that it expects to receive CAD 0.96 million in funding from Medigus Ltd.

Análisis de compensación del CEO

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad